Zacks Investment Research upgraded shares of CryoPort Inc (CYRX) from NEUTRAL to OUTPERFORM on August 21, 2013, with a target price of $1.90.
In addition to the new leadership we see several catalysts to near-term revenue growth including resolution of the issues related to FedEx and the CryoPortal interface, the recent addition of new shipper sizes, a new focus on qualifying customers and identifying the low-hanging fruit, and the newly introduced broader menu of shipper and service offerings to appeal to a more diverse customer base. The long, drawn-out tire-kicking process by potential customers will likely continue to be a necessary evil before some customers adopt the full CryoPort Express Solution (which we still view as CYRX's long-term growth driver) but ancillary offerings should provide a meaningful contribution to the top-line and help cash generation in the near-term. The new deal to manage Pfizer's animal vaccines biz could be significant for CYRX for both financial and reputational reasons. Moving rec to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CryoPort Inc (CYRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment